RECIST v1.1Standard Response Criteria for Solid Tumors

Radiographic Category

Assign Response Category

Scoring Definition

CR: Disappearance of all target and non-target lesions.
PR: ≥ 30% decrease in sum of diameters of target lesions.
PD: ≥ 20% increase in sum of diameters, or new lesions.
SD: Neither PR nor PD criteria met.

Response Outlook

SD

Clinical Strategy

Stable Disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Used across almost all solid tumor Phase II and III clinical trials.

Dictates the primary endpoints of Objective Response Rate (ORR) and Progression-Free Survival (PFS).

Used in routine practice to definitively rule whether a patient should continue their current cytotoxic or targeted therapy.

How it Works

Target Lesion Rules

A maximum of 5 target lesions total (and max 2 per organ) are selected at baseline. They must be measurable: ≥ 10 mm longest diameter on CT (or ≥ 15 mm short axis for lymph nodes). The sum of their longest diameters (SLD) is calculated and tracked over time.

Response Thresholds

Category	Definition (Target Lesions)
Complete Response (CR)	Disappearance of all target and non-target lesions. All pathological lymph nodes must shrink to < 10 mm.
Partial Response (PR)	At least a 30% decrease in the SLD, taking as reference the baseline sum.
Progressive Disease (PD)	At least a 20% increase in the SLD (taking as reference the smallest sum recorded), AND an absolute increase of ≥ 5 mm. Appearance of one or more new lesions is automatically PD.
Stable Disease (SD)	Neither sufficient shrinkage for PR nor sufficient increase for PD.

Last Comprehensive Review: 2026

RECIST v1.1Standard Response Criteria for Solid Tumors

Radiographic Category

Assign Response Category

Scoring Definition

CR: Disappearance of all target and non-target lesions.
PR: ≥ 30% decrease in sum of diameters of target lesions.
PD: ≥ 20% increase in sum of diameters, or new lesions.
SD: Neither PR nor PD criteria met.

Response Outlook

SD

Clinical Strategy

Stable Disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Used across almost all solid tumor Phase II and III clinical trials.

Dictates the primary endpoints of Objective Response Rate (ORR) and Progression-Free Survival (PFS).

Used in routine practice to definitively rule whether a patient should continue their current cytotoxic or targeted therapy.

How it Works

Target Lesion Rules

Response Thresholds

Category	Definition (Target Lesions)
Complete Response (CR)	Disappearance of all target and non-target lesions. All pathological lymph nodes must shrink to < 10 mm.
Partial Response (PR)	At least a 30% decrease in the SLD, taking as reference the baseline sum.
Progressive Disease (PD)	At least a 20% increase in the SLD (taking as reference the smallest sum recorded), AND an absolute increase of ≥ 5 mm. Appearance of one or more new lesions is automatically PD.
Stable Disease (SD)	Neither sufficient shrinkage for PR nor sufficient increase for PD.

Last Comprehensive Review: 2026

RECIST 1.1

Radiographic Category

SD

When to Use

Clinical Use

How it Works

Target Lesion Rules

Response Thresholds

Clinical Pearls

The Non-Target Lesion Pitfall

The Evidence

Key Reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Related Tools

Recent Journal Updates

RECIST 1.1

Radiographic Category

SD

When to Use

Clinical Use

How it Works

Target Lesion Rules

Response Thresholds

Clinical Pearls

The Non-Target Lesion Pitfall

The Evidence

Key Reference

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Related Tools

Recent Journal Updates